DRMA
Dermata Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
Gap Down
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DRMA
Dermata Therapeutics, Inc.
A clinical-stage biotech company focusing on the treatment of medical and aesthetic skin conditions
3525 Del Mar Heights Rd., #322, San Diego, CA 92130
--
Dermata Therapeutics, Inc., in Delaware in December 2014. They are a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative drug candidates for the treatment of medical and aesthetic skin diseases and conditions, which the company believes represent a significant market opportunity due to the lack or non-existence of current therapies.
Company Financials
EPS
DRMA has released its 2025 Q2 earnings. EPS was reported at -1.66, versus the expected -0.44, missing expectations. The chart below visualizes how DRMA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
